TABLE 3.
Antifungal susceptibility test results for selected species of Candida isolated during prospective, sentinel surveillance in Brazil in 2003 and 2004
| Species (na) | Antifungal agent | MIC (μg/ml)
|
% Resistantb (no. of isolates) | ||
|---|---|---|---|---|---|
| Range | 50% | 90% | |||
| C. albicans (291) | Amphotericin B | 0.125-1.0 | 0.5 | 1.0 | 0 |
| Fluconazole | 0.125-64 | 0.25 | 0.5 | 0.3 (1) | |
| Itraconazole | 0.03-1.0 | 0.03 | 0.03 | 0.3 (1) | |
| 5-Flucytosine | 0.125-64 | 0.25 | 2.0 | 0.3 (1) | |
| Voriconazole | 0.03-4.0 | 0.03 | 0.03 | 0.3 (1) | |
| C. tropicalis (149) | Amphotericin B | 0.125-1.0 | 0.5 | 1.0 | 0 |
| Fluconazole | 0.125-32 | 0.5 | 1.0 | 0 | |
| Itraconazole | 0.03-0.25 | 0.03 | 0.125 | 0 | |
| 5-Flucytosine | 0.05-64 | 0.25 | 1.0 | 3 (5) | |
| Voriconazole | 0.03-0.5 | 0.03 | 0.06 | 0 | |
| C. parapsilosis (146) | Amphotericin B | 0.25-1.0 | 1.0 | 1.0 | 0 |
| Fluconazole | 0.125-8.0 | 1.0 | 4.0 | 0 | |
| Itraconazole | 0.03-0.5 | 0.03 | 0.125 | 0 | |
| 5-Flucytosine | 0.125-64 | 0.25 | 0.5 | 1.4 (2) | |
| Voriconazole | 0.03-0.25 | 0.03 | 0.06 | 0 | |
| C. pelliculosa (44) | Amphotericin B | 0.125-2.0 | 0.25 | 0.75 | 0 |
| Fluconazole | 0.5-16 | 4.0 | 8.0 | 0 | |
| Itraconazole | 0.03-0.5 | 0.125 | 0.5 | 0 | |
| 5-Flucytosine | 0.125-16 | 0.125 | 0.125 | 0 | |
| Voriconazole | 0.03-0.25 | 0.06 | 0.25 | 0 | |
| C. glabrata (35) | Amphotericin B | 0.25-1.0 | 0.5 | 1.0 | 0 |
| Fluconazole | 2.0-64 | 8.0 | 32 | 6 (2) | |
| Itraconazole | 0.03-32 | 0.25 | 4 | 34 (12) | |
| 5-Flucytosine | 0.125-8.0 | 0.125 | 0.25 | 0 | |
| Voriconazole | 0.03-2.0 | 0.125 | 1.0 | 0 | |
a
n, no. of isolates.
b
Resistance breakpoints: fluconazole, MIC of ≥64 μg/ml; itraconazole, ≥1 μg/ml; flucytosine, ≥32 μg/ml; amphotericin B, ≥2 μg/ml; voriconazole, ≥4 μg/ml.